Sword refers to the second growth curve of Antu creature in the PCR Laboratory

[Dahe Daily · Dahecai Cube] (Reporter Tang Dynasty Jin) Time is not upset. After years of attaching importance to research and development, Antu creatures are entering the harvest period.

On August 17, the Antu Biological 2022 Half -annual Daily was officially released. Relying on the steady growth of the traditional chemical emitting sector, the revenue and net profit of Antu Biological have maintained an increase of more than 20%.

At the same time, in the context of the construction of the PCR laboratory at or above the county level, with the many characteristics and advantages of the real -time fluorescence PCR analysis system independently developed, the second growth curve of Antu creatures has been opened.

Antu Biological Semi -annual Revenue has achieved dual growth in revenue and net profit

On August 17, Antu Bio announced the transcript in the first half of the year.

According to the semi -annual report data, during the reporting period, Antu Bio achieved operating income of 2.07 billion yuan, an increase of 23.41 % year -on -year; net profit attributable to shareholders of listed companies was 534 million yuan, an increase of 29.28 % year -on -year; The net profit of sexual profit and loss was 505 million yuan, an increase of 25.40%year -on -year. Basic earnings per share are 0.91 yuan/share.

According to the data, Antu Biological was established in 1998. Its main business is the research and development, manufacturing, integration and service of in vitro diagnostic reagents and instruments. The products cover the fields of immunity, microorganism, biochemical, molecules, coagulation and other testing fields. Provide comprehensive product solutions and overall services.

As the domestic IVD industry leading enterprise, Antu Bio has always attached great importance to R & D. In the first half of this year, the R & D investment of Antu Bio was 253 million yuan, accounting for 12.21%of operating income.在持续研发高投入的基础上，公司相继取得了一系列创新成果：截至2022年6月30日，公司已获专利1033项(包含国际专利50项)，其中国内专利授权包含发明专利108项、 795 practical new patents and 80 exterior design patents; 617 product registration (filing) certificates, and obtained 435 EU CE certification. The company has undertaken 11 national projects, 18 provincial projects, 24 urban projects, and 10 items of scientific and technological achievements (evaluation).

Maintain stable growth in the chemical emitting sector

Although Antu Bio did not mention the profitability of various product sectors in the semi -annual report, it can be seen from the 2021 annual report and the first quarter report that after many years of continuous investment in R & D investment, Antu creatures have established establishment Centered on the assembly line, covering the entire series of diagnostic product lines such as immunity, biochemical, microorganisms, molecules, and coagulation.

Among them, in the chemical emitting sector, Antu creatures continue to maintain stable growth.

According to the CITIC Investment Research Report, although it continued to be impacted by the epidemic in 2021, the overall recovery of high growth trend was mainly due to the growth of reagent sales brought about by the continued high growth of the core business chemical lighting machine. 1200 units, the reagent production has recovered but it is still lower than the average level in 2019; the installation of automated assembly line A1 and B1 installation continues to advance steadily, further consolidating the leading position of the domestic pipeline. Recovered.

Regarding the newly released Antu Biological Semi -annual report, people related industries said in an interview with the Dahe News Daily Dahecai Cube reporter that from the perspective of financial data, as a traditional advantage project of Antu Bio, the chemical glow of Antu Biological in the first half of this year this year The product still maintains a high -speed growth trend, which has laid a solid foundation for the performance of Antu creatures.

Sword refers to the second growth curve of Antu creature in the PCR Laboratory

In fact, from the perspective of past financial data, in addition to the high -speed growth of the chemical light emitting sector, Antu creatures finally made Antu creatures in the field of molecular diagnosis, and it also opened the second second to it. Growth curve.

In July 2021, Antu Bio launched a full -automatic nucleic acid purity and real -time fluorescent PCR analysis system (Automolec3000, Automolec1600), and innovatively realized a single sample or small -batches The medical laboratory provides more sensitive, convenient and efficient nucleic acid testing products. In the same month, Antu's new nucleic acid testing kit (PCR-fluorescent probe) was obtained by the "Medical Device Registration Certificate" issued by the State Drug Administration.

"Compared with the previous PCR analysis equipment, the nucleic acid detection equipment of Antu organisms has been fully automatic, saving a lot of manpower for the hospital laboratory. Efficiency. More importantly, with the traditional PCR detection 96 or 48 -hole board, dozens of samples need to be accumulated to do a test. Compared with, the PCR device launched by Antu creatures can not only achieve a single specimen with the same specimen. In the future, at least 20 items other than new crown pneumonia can be achieved in the future. This is currently the exclusive product in China. "Cheng Xincheng Pharmaceutical Industry Analyst Cheng Pei said in an interview with the Dahe News Dahe Cai Cube.

It is understood that in August 2020, the State Council officially issued the "Further Promoting Promoting Work Plan for the Construction of New Crown Virus Nucleic acid Detection Capacity". The plan is clearly clear that by the autumn and winter of 2020, the country includes three -level comprehensive hospitals, infectious disease hospitals, disease control centers, and counties in the county area. A county -level hospital with strong technical power must complete the construction of the PCR laboratory. As a result, the construction of PCR laboratories in the country ushered in a big explosion. Relevant industry data shows that as of now, the domestic PCR laboratory has reached more than 11,000.

It is precisely because of the innovation capabilities in the field of PCR equipment that in the context of the construction of PCR laboratories at or above the county level nationwide, it has opened a brand new market for Antu creatures.

At present, the equipment in the domestic PCR laboratory can only detect a project such as new crown pneumonia and A stream, but Antu Bio's fully automatic nucleic acid detection and analysis system (Automolec3000, Automolec1600) can be detected at the same time. For the laboratory, not only does the detection efficiency improve, but also a single random, the characteristics of the admission can also provide more diverse detection services for the hospital PCR laboratory.

The response from the market also proves the advantages of Antu creatures in the PCR laboratory. According to relevant people familiar with the matter, in the first half of this year, the installed capacity of the PCR analysis system of Antu Bio has maintained a high -speed growth per month.

"Because of the uniqueness of the Antu biological nucleic acid detection equipment, it takes a certain amount of time for other domestic companies to meet this standard. This is undoubtedly opened up the second growth curve for Antu Bio." Relevant industry personnel said Essence

Responsible editor: Chen Yuyao | Review: Li Zhen | Director: Wan Junwei

- END -